The network pharmacology and pathway enrichment analysis predicted that EGFR, PI3K, and AKT1 was increasingly associated pathway with the anti-tumor properties of 18α-GA in NSCLC. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.